Skip to main content

Menu

Select a tool from the sidebar

Create your free account now!

Sign in to customize and use tools on the sidebar.

Sign InCreate free account
Pfizer Inc. logo
PFE
Pfizer Inc.
19:59:59
25.22 $
0.0000 (%0.00)
Previous Close: 25.92
Day Low₺24.94
Day High₺25.66
Bid
Ask
Overview
Technicals
Financial Statements
Comments
Archive

PFE: Pfizer Inc. Financials

Pfizer Inc. Income Statement

Total revenue
Net income
Gross margin TTM
70.33%
Operating margin TTM
24.67%
Net profit margin TTM
12.42%
Return on investment TTM
8.99%
Period end31/12/202531/12/202431/12/202331/12/2022
Total revenue62,579,000,00063,627,000,00059,553,000,000100,330,000,000
Operating income15,437,000,00016,483,000,0005,292,000,00037,549,000,000
Net income7,770,000,0008,020,000,0002,133,000,00031,365,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Total revenue62,579,000,00063,627,000,00059,553,000,000100,330,000,000
Cost of revenue18,565,000,00021,781,000,00029,213,000,00038,240,000,000
Gross profit44,014,000,00041,846,000,00030,340,000,00062,090,000,000
Research and development expenses11,976,000,00010,738,000,00010,578,000,00011,426,000,000
General and administrative expenses011,471,000,00000
Selling and marketing expenses03,300,000,00000
Selling, general and administrative expenses13,346,000,00014,730,000,00014,470,000,00013,115,000,000
Other expenses3,255,000,000-105,000,00000
Operating expenses28,577,000,00025,363,000,00025,048,000,00024,541,000,000
Cost and expenses47,142,000,00047,144,000,00054,261,000,00062,781,000,000
Net interest income-2,068,000,000-2,546,000,000-585,000,000-987,000,000
Interest income603,000,000545,000,0001,624,000,000251,000,000
Interest expense2,671,000,0003,091,000,0002,209,000,0001,238,000,000
Depreciation and amortization4,905,000,0007,013,000,0006,290,000,0005,064,000,000
EBITDA15,096,000,00018,127,000,0009,557,000,00041,031,000,000
EBIT10,191,000,00011,114,000,0003,267,000,00035,967,000,000
Non-operating income (excl. interest)5,246,000,0005,369,000,0002,025,000,0001,582,000,000
Operating income15,437,000,00016,483,000,0005,292,000,00037,549,000,000
Total other income/expenses (net)-7,917,000,000-8,460,000,000-4,234,000,000-2,820,000,000
Income before tax7,520,000,0008,023,000,0001,058,000,00034,729,000,000
Income tax expense-266,000,000-28,000,000-1,114,000,0003,328,000,000
Net income from continuing operations7,786,000,0008,051,000,0002,172,000,00031,401,000,000
Net income from discontinued operations25,000,00011,000,0000-1,000,000
Other adjustments to net income0000
Net income7,770,000,0008,020,000,0002,133,000,00031,365,000,000
Net income deductions0-11,000,00014,000,0000
Bottom line net income7,745,000,0008,031,000,0002,119,000,00031,365,000,000
EPS110.37556
Diluted EPS110.37125
Weighted average shares outstanding5,682,759,0005,664,000,0005,643,000,0005,608,000,000
Weighted average diluted shares outstanding5,686,000,0005,700,000,0005,709,000,0005,733,000,000

Pfizer Inc. Balance Sheet

Total assets
Total liabilities & equity
Liquidity ratio MRQ
—
Current ratio MRQ
—
Long-term debt / assets MRQ
61,641,000,000%
Total debt / assets MRQ
—
Period end31/12/202531/12/202431/12/202331/12/2022
Total assets208,160,000,000213,396,000,000226,501,000,000197,206,000,000
Total liabilities121,385,000,000124,899,000,000137,213,000,000101,289,000,000
Total equity86,476,000,00088,203,000,00089,014,000,00095,661,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Cash and cash equivalents1,142,000,0001,043,000,0002,853,000,000416,000,000
Short-term investments12,454,000,00019,434,000,0009,837,000,00022,316,000,000
Cash and short-term investments13,596,000,00020,477,000,00012,690,000,00022,732,000,000
Net receivables15,841,000,00014,777,000,00015,544,000,00014,529,000,000
Accounts receivable11,874,000,00011,463,000,00011,566,000,00010,952,000,000
Other receivables3,967,000,0003,314,000,0003,978,000,0003,577,000,000
Inventory10,654,000,00010,851,000,00010,189,000,0008,981,000,000
Prepaid expenses0000
Other current assets2,807,000,0004,253,000,0004,910,000,0005,017,000,000
Total current assets42,898,000,00050,358,000,00043,333,000,00051,259,000,000
Property, plant and equipment (net)21,530,000,00018,393,000,00018,940,000,00016,274,000,000
Goodwill71,264,000,00068,527,000,00067,783,000,00051,375,000,000
Intangible assets53,731,000,00055,412,000,00064,900,000,00043,370,000,000
Goodwill and intangible assets124,995,000,000123,939,000,000132,683,000,00094,745,000,000
Long-term investments1,737,000,0002,227,000,00015,368,000,00015,069,000,000
Tax assets9,699,000,0008,662,000,0003,706,000,0006,693,000,000
Other non-current assets7,301,000,0009,817,000,00012,471,000,00013,163,000,000
Total non-current assets165,262,000,000163,038,000,000183,168,000,000145,944,000,000
Other assets0003,000,000
Total assets208,160,000,000213,396,000,000226,501,000,000197,206,000,000
Total payables10,788,000,00010,980,000,00011,431,000,00010,699,000,000
Accounts payable5,240,000,0005,633,000,0006,710,000,0006,809,000,000
Other payables5,548,000,0005,347,000,0004,721,000,0003,890,000,000
Accrued expenses3,610,000,000000
Short-term debt3,484,000,0006,946,000,00010,346,000,0002,934,000,000
Capital lease obligations (current)0356,000,00000
Tax payables002,349,000,0001,587,000,000
Deferred revenue784,000,0001,511,000,0002,700,000,0002,520,000,000
Other current liabilities18,318,000,00023,202,000,00023,317,000,00025,985,000,000
Total current liabilities36,984,000,00042,995,000,00047,794,000,00042,138,000,000
Long-term debt61,641,000,00057,405,000,00060,499,000,00031,925,000,000
Capital lease obligations (non-current)2,291,000,0002,286,000,00000
Deferred revenue (non-current)0000
Deferred tax liabilities (non-current)2,401,000,0002,122,000,000640,000,0001,023,000,000
Other non-current liabilities18,068,000,00020,091,000,00028,280,000,00026,203,000,000
Total non-current liabilities84,401,000,00081,904,000,00089,419,000,00059,151,000,000
Other liabilities0000
Capital lease obligations2,291,000,0002,642,000,00000
Total liabilities121,385,000,000124,899,000,000137,213,000,000101,289,000,000
Treasury stock-115,015,000,000-114,763,000,000-114,487,000,000-113,969,000,000
Preferred stock0000
Common stock481,000,000480,000,000478,000,000476,000,000
Retained earnings114,610,000,000116,725,000,000118,353,000,000125,656,000,000
Additional paid-in capital94,469,000,00093,603,000,00092,631,000,00091,802,000,000
Accumulated other comprehensive income/loss-8,069,000,000-7,842,000,000-7,961,000,000-8,304,000,000
Other stockholders' equity0000
Total stockholders' equity86,476,000,00088,203,000,00089,014,000,00095,661,000,000
Total equity86,775,000,00088,497,000,00089,288,000,00095,917,000,000
Minority interest299,000,000294,000,000274,000,000256,000,000
Total liabilities and total equity208,160,000,000213,396,000,000226,501,000,000197,206,000,000
Total investments14,191,000,00021,661,000,00025,205,000,00037,385,000,000
Total debt67,416,000,00066,993,000,00070,845,000,00034,859,000,000
Net debt66,274,000,00065,950,000,00067,992,000,00034,443,000,000

Pfizer Inc. Cash Flow Statement

Cash from operations
Cash from investing
Cash flow / share TTM
—
Revenue / share TTM
—
Operating cash flow TTM
—
Period end31/12/202531/12/202431/12/202331/12/2022
Cash from operations11,705,000,00012,744,000,0008,700,000,00029,267,000,000
Cash from investing-1,351,000,0002,652,000,000-32,278,000,000-15,783,000,000
Cash from financing-10,304,000,000-17,140,000,00026,066,000,000-14,834,000,000
Net change in cash99,000,000-1,810,000,0002,449,000,000-1,515,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Net income7,746,000,0008,051,000,0002,172,000,00031,401,000,000
Depreciation and amortization6,592,000,0007,013,000,0006,290,000,0005,064,000,000
Deferred income tax-2,133,000,000-2,102,000,000-3,442,000,000-3,764,000,000
Stock-based compensation0877,000,000525,000,000872,000,000
Change in working capital-5,354,000,000-3,066,000,000-2,172,000,000-4,456,000,000
Accounts receivable-263,000,000-109,000,000347,000,000261,000,000
Inventory561,000,000-854,000,0006,199,000,000592,000,000
Accounts payable-469,000,000-1,023,000,000-300,000,0001,191,000,000
Other working capital-5,183,000,000-1,080,000,000-8,418,000,000-6,500,000,000
Other non-cash items4,854,000,0001,971,000,0005,327,000,000150,000,000
Net cash from operating activities11,705,000,00012,744,000,0008,700,000,00029,267,000,000
Investments in property, plant and equipment-2,629,000,000-2,909,000,000-3,907,000,000-3,236,000,000
Acquisitions (net)-6,927,000,0007,040,000,000-43,430,000,000-22,997,000,000
Purchases of investments-14,650,000,000-10,313,000,000-31,178,000,000-38,780,000,000
Sales/maturities of investments22,690,000,0008,834,000,00046,417,000,00045,462,000,000
Other investing activities165,000,0000-180,000,0003,768,000,000
Net cash from investing activities-1,351,000,0002,652,000,000-32,278,000,000-15,783,000,000
Net debt issuance-74,000,000-7,159,000,00035,945,000,000-3,516,000,000
Long-term net debt issuance2,921,000,000-2,250,000,00028,262,000,000-3,298,000,000
Short-term net debt issuance-2,995,000,000-4,909,000,0007,683,000,000-218,000,000
Net stock issuance000-2,000,000,000
Net common stock issuance000-2,000,000,000
Common stock issuance0000
Common stock repurchased000-2,000,000,000
Net preferred stock issuance0000
Net dividends paid-9,771,000,000-9,512,000,000-9,247,000,000-8,983,000,000
Common dividends paid-9,771,000,000-9,512,000,000-9,247,000,000-8,983,000,000
Preferred dividends paid0000
Other financing activities-459,000,000-469,000,000-632,000,000-335,000,000
Net cash from financing activities-10,304,000,000-17,140,000,00026,066,000,000-14,834,000,000
Effect of FX changes on cash49,000,000-66,000,000-40,000,000-165,000,000
Net change in cash99,000,000-1,810,000,0002,449,000,000-1,515,000,000
Cash at end of period1,142,000,0001,107,000,0002,917,000,000468,000,000
Cash at beginning of period1,043,000,0002,917,000,000468,000,0001,983,000,000
Operating cash flow11,705,000,00012,744,000,0008,700,000,00029,267,000,000
Capital expenditure-2,629,000,000-2,909,000,000-3,907,000,000-3,236,000,000
Free cash flow9,076,000,0009,835,000,0004,793,000,00026,031,000,000
Income taxes paid03,605,000,0003,147,000,0007,867,000,000
Interest paid03,227,000,0002,215,000,0001,442,000,000